Physician profile
Thomas E Wills
NPI 1578523981
$2,861.32
in general payments reported to CMS, 2019-2025
37 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $338 · 2021: $621 · 2022: $349 · 2023: $464 · 2024: $343 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $476.12 | 2019-2025 | Xtandi, Myrbetriq |
| Abbvie INC. | $286.08 | 2020-2024 | Botox |
| Boston Scientific Corporation | $284.54 | 2019-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Ams 700 Cxr Rte Kit |
| Urogen Pharma, INC. | $252.88 | 2023-2025 | Jelmyto |
| Janssen Biotech, INC. | $225.14 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $172.48 | 2020-2025 | |
| Tolmar Pharmaceuticals, INC. | $118.52 | 2019-2022 | |
| Blue Earth Diagnostics | $91.78 | 2020-2021 | |
| Antares Pharma, INC. | $84.91 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Endo USA, INC. | $84.33 | 2024-2025 | Aveed, Xiaflex |
| Accord Healthcare, INC. | $78.23 | 2023 | |
| Pfizer INC. | $70.54 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $65.89 | 2023-2024 | Gemtesa, Orgovyx |
| Tolmar, INC. | $45.03 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $44.33 | 2021-2024 | Keytruda |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.